Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 - Clinical Trial Optional)
The purpose of this initiative is to request applications that aim to implement and evaluate multi-level interventions and community engaged research in advancing vision equity. This Notice of Funding Opportunity (NOFO) supports research directed at preventing, reducing, or eliminating disparities in eye and vision health. Applications responding to this NOFO must involve multilevel interventions that simultaneously address vision health conditions and social determinants of health (SDOH) at one or more levels of influence, such as individual, interpersonal, organizational, and community. Research must include a focus on improving vision health in one or more NIH-designated Populations with Health Disparities. Additionally, research must demonstrate meaningful community engagement in the research process.
Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional)
The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support unusually innovative intervention research addressing social determinants of health (SDOH) which, if successful, would have a major impact on preventing, reducing, or eliminating health disparities and advancing health equity. Projects should clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on advancing NIH’s commitment to addressing SDOH to accelerate progress in improving health for all. Preliminary data are not required for this initiative.
This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This NOFO seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases, including the promotion of health equity, within the mission of the NIDDK.
NIAID, NIDDK, NIDA, and NIAAA Research Opportunities for New and "At-Risk" Investigators (R01 Clinical Trial Optional)
The purpose of this notice of funding opportunity (NOFO) is to encourage New and ‘At-risk’ Investigators from diverse backgrounds, including but not limited to individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical, and social sciences, to work with their institutions to submit applications for research projects within the mission of NIAID, NIDDK, NIDA, or NIAAA. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.
Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research network infrastructure relevant to infants, children, women, pregnant and lactating individuals, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical study implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.
This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)
to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.